What is HC Wainwright’s Forecast for IOVA Q3 Earnings?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Equities researchers at HC Wainwright lifted their Q3 2026 earnings estimates for Iovance Biotherapeutics in a note issued to investors on Thursday, August 6th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will earn ($0.12) per share for the quarter, up from their previous estimate of ($0.17). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.58) EPS and FY2027 earnings at ($0.35) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.92%. The firm had revenue of $198.63 million during the quarter, compared to analysts’ expectations of $87.83 million. During the same period in the previous year, the company earned ($0.33) EPS. The firm’s revenue for the quarter was up 65.7% compared to the same quarter last year.

Several other brokerages have also issued reports on IOVA. Citigroup restated an “outperform” rating on shares of Iovance Biotherapeutics in a research report on Friday. Chardan Capital reduced their price target on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Citizens Jmp raised their price target on Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Friday. Robert W. Baird set a $6.00 price objective on Iovance Biotherapeutics in a report on Friday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Thursday, July 2nd. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $8.00.

Iovance Biotherapeutics Price Performance

Iovance Biotherapeutics stock opened at $6.40 on Monday. Iovance Biotherapeutics has a 1-year low of $1.76 and a 1-year high of $6.92. The firm has a market capitalization of $2.90 billion, a P/E ratio of -8.77 and a beta of 0.71. The company’s 50-day moving average is $4.45 and its 200 day moving average is $3.84.

Hedge Funds Weigh In On Iovance Biotherapeutics

A number of large investors have recently bought and sold shares of the business. KBC Group NV bought a new stake in Iovance Biotherapeutics during the 1st quarter valued at $34,000. Arcataur Capital Management LLC bought a new position in shares of Iovance Biotherapeutics in the 4th quarter worth $29,000. Granite Investment Partners LLC purchased a new stake in shares of Iovance Biotherapeutics during the 4th quarter worth $29,000. Motley Fool Asset Management LLC purchased a new stake in shares of Iovance Biotherapeutics during the 4th quarter worth $29,000. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Iovance Biotherapeutics during the 1st quarter worth $38,000. Institutional investors own 77.03% of the company’s stock.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.